Johnson & Johnson (JNJ)
| Market Cap | 635.76B +37.6% |
| Revenue (ttm) | 99.34B +7.8% |
| Net Income | 16.10B -35.9% |
| EPS | 6.58 -36.4% |
| Shares Out | 2.41B |
| PE Ratio | 40.07 |
| Forward PE | 23.69 |
| Dividend | $5.36 (2.03%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | 5,309,356 |
| Open | 265.82 |
| Previous Close | 267.61 |
| Day's Range | 262.40 - 266.03 |
| 52-Week Range | 184.66 - 281.07 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 279.41 (+5.91%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $279.41, which is an increase of 5.91% from the latest price.
News
UK approves J&J's oral psoriasis pill
Britain's medicines regulator on Friday approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy...
Johnson & Johnson reports real-world VARIPULSE Pro platform data
Johnson & Johnson announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society 2026 Annual Meeting in Busan, South Korea. Both studies…
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment.
3 of the Best Value Stocks to Own
#StockstoBuy #ValueStocks #TheMorningFilter These value stocks with wide economic moats are good long-term investments when you can buy them at a discount.
Johnson & Johnson downgraded to Hold from Buy at Erste Group
Erste Group downgraded Johnson & Johnson to Hold from Buy. On a sector-by-sector basis, the stock is trading at a high valuation, which leads the firm to believe its upside…
Johnson & Johnson announces U.S. launch of Shockwave C2 Aero Fly catheter
Johnson & Johnson announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified coronary artery lesions in half the…
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
SANTA CLARA, Calif.--(BUSINESS WIRE)--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026
ABU DHABI, United Arab Emirates--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson will showcase digital surgery technologies and its Department of Health - Abu Dhabi collaboration at the Future Heal...
Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn's disease and expanding evidence in perianal fistula
BEERSE, BELGIUM (19 October 2026) – Johnson & Johnson today announced new data that further expands the clinical evidence supporting TREMFYA® (guselkumab) in Crohn's disease (CD) at the 2026 United Eu...
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally
Johnson & Johnson’s ($JNJ) rally has me holding off, despite an improving business. The global healthcare products maker raised its full-year guidance in the Q3 2026 earnings report released on…
Johnson & Johnson reports results from Phase 3 FUZION study
Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease, or…
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings...
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $JNJ--JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law.
Johnson & Johnson price target raised to $287 from $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Johnson & Johnson (JNJ) to $287 from $275 and keeps an Overweight rating on the shares. With 100% deal…
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pil...
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Johnson & Johnson price target lowered to $292 from $294 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $292 from $294 and keeps an Overweight rating on the shares. The company posted “a generally in-line” Q3…
Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)
China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.
Johnson & Johnson price target lowered to $280 from $290 at RBC Capital
RBC Capital lowered the firm’s price target on Johnson & Johnson to $280 from $290 and keeps an Outperform rating on the shares. The stock’s 6% decline after in-line results…
Johnson & Johnson price target lowered to $272 from $276 at Leerink
Leerink lowered the firm’s price target on Johnson & Johnson to $272 from $276 and keeps an Outperform rating on the shares. Although 2027 results will be constrained by certain…
Johnson & Johnson price target lowered to $275 from $282 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Johnson & Johnson to $275 from $282 and keeps a Neutral rating on the shares, stating that the company delivered…
Johnson & Johnson price target lowered to $275 from $282 at Wells Fargo
Wells Fargo lowered the firm’s price target on Johnson & Johnson to $275 from $282 and keeps an Overweight rating on the shares. Despite Q3 beat/2026 guide raise, J&J was…
Johnson & Johnson price target lowered to $275 from $282 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Johnson & Johnson to $275 from $282 and keeps an Overweight rating on the shares. Despite Q3 beat/2026 guide…
Johnson & Johnson price target raised to $270 from $261 at Bernstein
Bernstein raised the firm’s price target on Johnson & Johnson to $270 from $261 and keeps a Market Perform rating on the shares. The firm notes J&J reported a solid…
Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
Johnson & Johnson executive vice president and CFO Joe Wolk discusses the company's third-quarter earnings, raising its full-year guidance, a potential spinoff of its DePuy Synthes orthopedics unit, a...